SPARC

What Sun Pharma Advanced Research Company promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q3 FY26

what the last two calls moved 17 tracked 3 delivered 4 missed 10 open
  • PROSEEK (PD Phase-2) Data Readout missed said Q1 FY23 Promised: Coming financial year (H2 FY24) Q3 FY26: The trial failure is a past event and was not discussed. The outcome remains a miss.
  • Cash Runway at risk said Q1 FY23 Promised: End of FY'24 Q3 FY26: Reiterated that the company is finalizing a funding plan to extend the cash window to FY'28, with completion hoped for in H1 2026. The previous runway is exhausted and the new funding is not yet secured.
  • SCD-153 Phase 1B Interim Readout open said Q3 FY26 Promised: Q4 of the calendar year 2026 Q3 FY26: An interim readout from the Phase 1B study in alopecia areata is expected in the Q4 of the calendar year 2026.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 17 tracked commitments for Sun Pharma Advanced Research Company — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens